Immunic, Inc. (IMUX)
- Previous Close
1.2400 - Open
1.2300 - Bid 1.2500 x 400
- Ask 1.2800 x 400
- Day's Range
1.1900 - 1.2700 - 52 Week Range
0.9450 - 3.1100 - Volume
244,880 - Avg. Volume
590,438 - Market Cap (intraday)
113.5M - Beta (5Y Monthly) 1.95
- PE Ratio (TTM)
-- - EPS (TTM)
-2.1100 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.50
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
imux.comRecent News: IMUX
Performance Overview: IMUX
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IMUX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IMUX
Valuation Measures
Market Cap
113.50M
Enterprise Value
68.16M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.92
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.69
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-68.13%
Return on Equity (ttm)
-131.28%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-93.61M
Diluted EPS (ttm)
-2.1100
Balance Sheet and Cash Flow
Total Cash (mrq)
46.67M
Total Debt/Equity (mrq)
4.61%
Levered Free Cash Flow (ttm)
-39.98M